Guide to the 2022 Subject Index

Committee mandate: The Select Special Committee to Examine Safe Supply was established by the Legislative Assembly through the passage of Government Motion 115 on December 7, 2021. The committee must report to the Legislative Assembly with recommendations by April 30, 2022.

The committee's mandate is limited to consideration of:

- a. examining the concept of "safe supply," defined as the provision of pharmaceutical opioids, heroin, crystal methamphetamine, cocaine, or other substances to people who are addicted to or dependent on these substances;
- b. whether there is evidence that a proposed "safe supply" would have an impact on fatal or non-fatal overdose, drug diversion, or associated health and community impacts;
- c. whether there is evidence that a proposed "safe supply" would be accompanied by increased risks to individuals, the community, other entities or jurisdictions
- d. examining historical evidence regarding the over-prescribing of opioids; and
- e. whether there is evidence that a proposed "safe supply" would be accompanied by any other benefits or consequences.

There are two indexes for the transcripts of meetings of the Standing Committee on Alberta's Economic Future, a **subject index** and a **speaker index**. Interim indexes are unedited and are not considered official. Committee activities during the 30th Legislature, Third Session (February 22, 2022 –) are as follows.

Abbreviations

Political parties

Ind. Independent (no party affiliation)

NDP New Democratic Party UCP United Conservative Party

Abbreviations not included in the above list are in the subject index in alphabetical order.

Committee meeting dates and page ranges with links to transcripts:

Committee meeting dates	Pages
March 25, 2022 (stakeholder presentations)	ESS117-130
June 7. 2022	

Addiction, substance

See Substance abuse and addiction

Addiction and mental health strategy

Recovery-oriented system of care ... Fort ESS123-24

Addiction treatment

[See also Substance abuse and addiction]

Evidence-based medications, committee recommendation that government ensure health coverage ... *Allard* ESS135–36; *Frey* ESS135; *Koenig* ESS135–36; *Milliken* ESS135

Evidence-based medications, committee recommendation that government ensure health coverage, motion on (Allard: carried) ... Allard ESS136; Chair ESS136; Koenig ESS136 Funding ... Allard ESS125; Fort ESS125

Recovery-oriented system of care, committee recommendation to explore options for enhancing police ability to use alternatives to the criminal justice system ... Allard ESS141; Amery ESS140; Chair ESS140; Koenig ESS140; Milliken ESS139–41; Stephan ESS140

Recovery-oriented system of care, committee recommendation to explore options for enhancing police ability to use alternatives to the criminal justice system, motion on (Milliken: carried) ... *Milliken* ESS141

Alberta Medical Association

Presentation on safe supply ... Allard ESS133; Amery ESS136; Frey ESS132–33; Milliken ESS132; Robert ESS133

AMA

See Alberta Medical Association

Best, Dr. David (Participant, Safe Supply Review) Presentation on safe supply ... Allard ESS138

British Columbia Centre on Substance Use

Supplementary written submission on safe supply ... Chair ESS134

Canadian Association of People Who Use Drugs Written submission on safe supply ... Chair ESS134

Chief medical officer of health

Technical briefing on safe supply See Safe supply review, public/stakeholder oral presentations: Technical briefing by Health ministry

Chronic disease management

Pain management See Pain management

Commissions for the dissuasion of drug addiction, Portugal

See Substance use: Portuguese national strategy

Committee to Examine Safe Supply, Select Special

Agenda, June 7, 2022, meeting, return to section (b), report of the committee to the Assembly (unanimous consent granted) ... *Chair* ESS143; *Robert* ESS143

Minutes of June 7, 2022, meeting to be approved by chair following review by members ... *Chair* ESS142–43

Minutes of June 7, 2022, meeting to be approved by chair following review by members, motion on (Allard: carried) ... *Allard* ESS143

Procedure on deliberation See Safe supply review: Committee deliberation procedure

Controlled Drugs and Substances Act (federal)

Exemptions ... Amato ESS126–27

Diseases, chronic

Pain management See Pain management

Drugs, illicit

Decriminalization ... Goulão ESS118, 121; Rosin ESS121; Yao ESS121

Drugs, prescription

[See also Pain management]

Opioid prescription for pain, committee recommendation to acknowledge damaging effect of overprescription and take steps to insulate medical education from pharmaceutical industry influence, motion on (Amery: carried) ... Amery ESS141

Opioid prescription for pain, committee recommendation to ensure physician education, motion on (Allard: carried) ... *Allard* ESS141–42

Opioid prescription for pain, committee recommendation to protect public from harmful pharmaceutic practices, motion on (Frey: carried) ... Frey ESS139

Use in addiction treatment See Addiction treatment: Evidence-based medications

Examine Safe Supply, Select Special Committee to See Committee to Examine Safe Supply, Select Special

Fentanyl treatment

See Addiction treatment

Fort, Amber

Presentation on safe supply ... Allard ESS125–26; Fort ESS122–26; Milliken ESS124–25; Yao ESS124, 126

Goulão, Dr. João

Presentation on safe supply ... Allard ESS120–21; Amery ESS119; Chair ESS119; Goulão ESS117– 22; Milliken ESS119, 121–22, 139; Rosin ESS121; Stephan ESS120; Yao ESS120–21

Kahan, Dr. Medlon

Written submission on safe supply ... Chair ESS134

Madras, Dr. Bertha (Participant, Safe Supply Review)
Presentation on safe supply ... *Allard* ESS137–38

Medical Association, Alberta

See Alberta Medical Association

Medication

See Drugs, prescription

Mental health and addiction strategy See Addiction and mental health strategy

Motions (committee)

Committee recommendation for provincial pain management strategy (Yao: carried) ... ESS137–38

Committee recommendation of health coverage for evidence-based medications used in addiction treatment (Allard: carried) ... ESS136

Committee recommendation that policies on safe supply consider interplay with diversion from intended user to illicit market (Frey: carried) ... ESS138–39

Committee recommendation to acknowledge damaging effect of overprescription of opioids and take steps to insulate medical education from pharmaceutical industry influence (Amery: carried) ... ESS141

Committee recommendation to allow for supply replacement in the context of a treatment plan under strict in-clinic supervision (Amery: carried) ... ESS137

Committee recommendation to ensure physician education on opioid prescription (Allard: carried) ... ESS141–42

Committee recommendation to explore options for enhancing police ability to use alternatives to criminal justice system (Milliken: carried) ... ESS141

Motions (committee) (continued)

Committee recommendation to protect public from harmful pharmaceutic practices (Frey: carried) ... ESS139

Draft report, inclusion of SFU report (Milliken: carried) ... ESS143

Draft report prepared by research services and approved by chair (Allard: carried) ... ESS142

Late written submissions accepted (Milliken: carried) ... ESS134

Late written submissions posted online (Milliken: carried) ... ESS134

Minutes of June 7, 2022, meeting approved by chair (Allard: carried) ... ESS143

Summary document of issues and proposals based on public/stakeholder input not attached to June 7, 2022, meeting minutes and reviewed by research services (Allard: carried) ... ESS133–34

Summary document of issues and proposals based on public/stakeholder input prepared by research services (Allard: carried) ... ESS128

Written submissions posted online with personal information removed (Yao: carried) ... ESS128

Written submissions received prior to March 14, 2022, accepted (Milliken: carried) ... ESS128

Opioid treatment

See Addiction treatment

Opioids

Diversion from medical use ... Amery ESS136

OUD (opioid use disorder) treatment See Addiction treatment

Pain management

Committee recommendation for provincial strategy ... Koenig ESS137; Stephan ESS137; Yao ESS137 Committee recommendation for provincial strategy, motion on (Yao: carried) ... Allard ESS137–38; Yao ESS137

Prescription drug use See Drugs, prescription

Pastew Place, Fort McMurray

Addiction treatment programs ... Allard ESS125–26; Fort ESS122–26; Milliken ESS124–25; Yao ESS124

Pharmaceuticals

See Drugs, prescription

Prescription drugs

See Drugs, prescription

Resolutions, debatable

See Motions (committee)

Safe supply

Committee recommendation that policies should consider diversion from intended user to illicit market ... Allard ESS138; Frey ESS138; Stephan ESS138

Committee recommendation that policies should consider interplay with diversion from intended user to illicit market, motion on (Frey: carried) ... *Chair* ESS139; *Frey* ESS138

Committee recommendation to allow for supply replacement in the context of a treatment plan under strict in-clinic supervision, motion on (Amery: carried) ... *Amery* ESS136–37

Crossjurisdictional comparison ... Allard ESS127; Amato ESS126–27; Chair ESS126; Yao ESS127 Federal funding ... Amato ESS127; Yao ESS127 General remarks ... Fort ESS123–24, 126; Yao ESS124, 126

Safe Supply, Select Special Committee to Examine See Committee to Examine Safe Supply, Select Special

Safe supply review

Committee deliberation ... *Allard* ESS135–38, 141–42; *Amery* ESS136–37, 140, 142; *Chair* ESS136–37, 140; *Frey* ESS135, 138–39; *Koenig* ESS135–37, 140; *Milliken* ESS135, 139–41; *Puttick* ESS135; *Stephan* ESS137–38, 140; *Yao* ESS137

Committee deliberation procedure ... Chair ESS128, 134

Scope of review ... Massolin ESS144; Yao ESS143

Safe supply review, public/stakeholder input

Summary document of issues and proposals ... Allard ESS132; Amato ESS131–33; Chair ESS131; Frey ESS132–33; Koenig ESS133; Massolin ESS132, 144; Milliken ESS131–33; Yao ESS133, 143

Summary document of issues and proposals, document to not be attached to meeting minutes and research services to review, motion on (Allard: carried) ... Allard ESS133; Frey ESS133-34

Summary document of issues and proposals to be prepared by research services, motion on (Allard: carried) ... *Allard* ESS128; *Chair* ESS128

Safe supply review, public/stakeholder oral presentations

Presenters *See* **Fort, Amber; Goulão, Dr. João** Technical briefing by Health ministry ... *Allard* ESS141–42

Safe supply review, public/stakeholder written submissions

Late submissions ... Chair ESS134; Yao ESS128 Late submissions accepted, motion on (Milliken: carried) ... Allard ESS134; Milliken ESS134

Late submissions posted online, motion on (Milliken: carried) ... ESS134

Late submissions received prior to March 14, 2022, accepted, motion on (Milliken: carried) ... *Chair* ESS128; *Milliken* ESS128

Posting online with personal information removed, motion on (Yao: carried) ... *Chair* ESS128; *Yao* ESS128

Summary ... Amato ESS127–28; Chair ESS127–28

Safe supply review report

Draft report ... Chair ESS142

Draft report to be prepared by research services and approved by chair following review by committee members, motion on (Allard: carried) ... Allard ESS142

Inclusion of SFU report A Public Supply of Addictive Drugs: A Rapid Review, motion on (Milliken: carried) ... *Milliken* ESS143

Inclusion of specific stakeholder input ... Allard ESS143; Chair ESS142-43; Milliken ESS142-43; Robert ESS142-43; Stephan ESS143

Safe supply review report recommendations

Interaction of addiction recovery and criminal justice system See Addiction treatment: Recovery-oriented system of care, committee recommendation to explore options for enhancing police ability to use alternatives to the criminal justice system

Medication coverage See Addiction treatment: Evidence-based medications, committee recommendation that government ensure health coverage

Safe supply review report recommendations (continued)

Opioid prescription practices See Drugs, prescription:
Opioid prescription for pain, committee
recommendation to acknowledge damaging effect
of overprescription and take steps to insulate
medical education from pharmaceutical industry
influence; Drugs, prescription: Opioid
prescription for pain, committee recommendation
to ensure physician education; Drugs,
prescription: Opioid prescription for pain,
committee recommendation to protect public from
harmful pharmaceutic practices

Pain management strategy development See Pain management: Committee recommendation for provincial strategy

Policy consideration of diversion of opioids to illicit market *See* Safe supply: Committee recommendation that policies should consider diversion from intended user to illicit market

Supervision of safe supply See Safe supply:
Committee recommendation to allow for supply replacement in the context of a treatment plan under strict in-clinic supervision

Select Special Committee to Examine Safe Supply See Committee to Examine Safe Supply, Select Special

Simon Fraser University (SFU)

Public Supply of Addictive Drugs: A Rapid Review ... Amery ESS141

Public Supply of Addictive Drugs: A Rapid Review, inclusion as appendix in committee report *See* Safe supply review report: Inclusion of SFU report

Substance abuse and addiction

Supervised consumption sites ... Amato ESS127 Treatment See Addiction treatment

Substance use

Harm reduction ... *Goulão* ESS118–19
Portuguese national strategy ... *Allard* ESS120–21; *Goulão* ESS117–21; *Stephan* ESS120; *Yao* ESS120
Portuguese national strategy, police role ... *Amery* ESS119; *Goulão* ESS119–20; *Milliken* ESS119
Portuguese national strategy, supply reduction ... *Goulão* ESS122; *Milliken* ESS122
Statistics, Portugal ... *Goulão* ESS117–19

Tanguay, Dr. Robert (Participant, Safe Supply Review) Presentation on safe supply ... Amery ESS141